Mastercard Q1 Earnings Beat Street View As Travel Spending Rebounds
Mastercard Incorporated (NYSE:MA) has reported Q1 sales of $5.2 billion, up 24% (28% currency-neutral), beating the consensus of $4.91 billion. Gross…
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine
GlaxoSmithKline Plc’s (NYSE:GSK) Q1 turnover reached £9.78 billion, up 32% Y/Y on actual exchange rate AER and constant exchange rate…
Investors Seem To Be Unmoved By IQVIA’s Street Lagging Estimates, Q1 Surpass Expectations
IQVIA Holdings Inc (NYSE:IQV) posted Q1 sales of $3.57 billion, up 4.7% on a reported basis and 6.8% at constant…
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours.
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
Molecular Partners AG’s (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners…
Medtronic Recalls Harmony Delivery Catheter Due Risk Of Breaking While Procedure
Medtronic Plc (NYSE:MDT) is recalling the Harmony Delivery Catheter, part of the Transcatheter Pulmonary Valve (TPV), due to the…
Centene Posts Street Beating Q1 Earnings, Lifts FY22 Outlook
Centene Corporation (NYSE:CNC) has reported a Q1 FY22 adjusted EPS of $1.83, compared to $1.63 a year ago, beating the…
Gilead’s Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28…
Why This Analyst Thinks HCA Healthcare Was ‘Well Oversold’ After Revised Outlook
RBC Capital Market reduced the target price for HCA Healthcare Inc (NYSE:HCA) from $291 to $267 (26.5% upside), noting the shares were…